172 related articles for article (PubMed ID: 10548568)
1. Enhanced secretory leukocyte protease inhibitor in human immunodeficiency virus type 1-infected patients.
Baqui AA; Meiller TF; Falkler WA
Clin Diagn Lab Immunol; 1999 Nov; 6(6):808-11. PubMed ID: 10548568
[TBL] [Abstract][Full Text] [Related]
2. Salivary secretory leukocyte protease inhibitor increases in HIV infection.
Lin AL; Johnson DA; Stephan KT; Yeh CK
J Oral Pathol Med; 2004 Aug; 33(7):410-6. PubMed ID: 15250833
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory function of secretory leukocyte proteinase inhibitor (SLPI) in human saliva is HIV-1 specific and varies with virus tropism.
Skott P; Lucht E; Ehnlund M; Björling E
Oral Dis; 2002 May; 8(3):160-7. PubMed ID: 12108760
[TBL] [Abstract][Full Text] [Related]
4. Salivary secretory leukocyte protease inhibitor is associated with reduced transmission of human immunodeficiency virus type 1 through breast milk.
Farquhar C; VanCott TC; Mbori-Ngacha DA; Horani L; Bosire RK; Kreiss JK; Richardson BA; John-Stewart GC
J Infect Dis; 2002 Oct; 186(8):1173-6. PubMed ID: 12355371
[TBL] [Abstract][Full Text] [Related]
5. Expression of oral secretory leukocyte protease inhibitor in HIV-infected subjects with long-term use of antiretroviral therapy.
Nittayananta W; Kemapunmanus M; Yangngam S; Talungchit S; Sriplung H
J Oral Pathol Med; 2013 Mar; 42(3):208-15. PubMed ID: 23126266
[TBL] [Abstract][Full Text] [Related]
6. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro.
McNeely TB; Dealy M; Dripps DJ; Orenstein JM; Eisenberg SP; Wahl SM
J Clin Invest; 1995 Jul; 96(1):456-64. PubMed ID: 7615818
[TBL] [Abstract][Full Text] [Related]
7. Anatomic dissociation between HIV-1 and its endogenous inhibitor in mucosal tissues.
Wahl SM; Worley P; Jin W; McNeely TB; Eisenberg S; Fasching C; Orenstein JM; Janoff EN
Am J Pathol; 1997 Apr; 150(4):1275-84. PubMed ID: 9094984
[TBL] [Abstract][Full Text] [Related]
8. Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV-I.
Wahl SM; McNeely TB; Janoff EN; Shugars D; Worley P; Tucker C; Orenstein JM
Oral Dis; 1997 May; 3 Suppl 1():S64-9. PubMed ID: 9456660
[TBL] [Abstract][Full Text] [Related]
9. Endogenous salivary inhibitors of human immunodeficiency virus.
Shugars DC; Alexander AL; Fu K; Freel SA
Arch Oral Biol; 1999 Jun; 44(6):445-53. PubMed ID: 10401522
[TBL] [Abstract][Full Text] [Related]
10. Human immunodeficiency virus type 1 stimulates the expression and production of secretory leukocyte protease inhibitor (SLPI) in oral epithelial cells: a role for SLPI in innate mucosal immunity.
Jana NK; Gray LR; Shugars DC
J Virol; 2005 May; 79(10):6432-40. PubMed ID: 15858026
[TBL] [Abstract][Full Text] [Related]
11. Salivary secretory leukocyte protease inhibitor and oral candidiasis in human immunodeficiency virus type 1-infected persons.
Chattopadhyay A; Gray LR; Patton LL; Caplan DJ; Slade GD; Tien HC; Shugars DC
Infect Immun; 2004 Apr; 72(4):1956-63. PubMed ID: 15039315
[TBL] [Abstract][Full Text] [Related]
12. Salivary concentration of secretory leukocyte protease inhibitor, an antimicrobial protein, is decreased with advanced age.
Shugars DC; Watkins CA; Cowen HJ
Gerontology; 2001; 47(5):246-53. PubMed ID: 11490143
[TBL] [Abstract][Full Text] [Related]
13. Comparison of human immunodeficiency virus type 1-specific inhibitory activities in saliva and other human mucosal fluids.
Kazmi SH; Naglik JR; Sweet SP; Evans RW; O'Shea S; Banatvala JE; Challacombe SJ
Clin Vaccine Immunol; 2006 Oct; 13(10):1111-8. PubMed ID: 16928883
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription.
McNeely TB; Shugars DC; Rosendahl M; Tucker C; Eisenberg SP; Wahl SM
Blood; 1997 Aug; 90(3):1141-9. PubMed ID: 9242546
[TBL] [Abstract][Full Text] [Related]
15. Estimation and comparison of salivary secretory leukocyte protease inhibitor in human immunodeficiency virus patients and healthy individuals.
Pushpanshu K; Sathawane RS; Kaushik R
Indian J Palliat Care; 2014 Jan; 20(1):26-30. PubMed ID: 24600179
[TBL] [Abstract][Full Text] [Related]
16. The role of the oral environment in HIV-1 transmission.
Shugars DC; Wahl SM
J Am Dent Assoc; 1998 Jul; 129(7):851-8. PubMed ID: 9685760
[TBL] [Abstract][Full Text] [Related]
17. Cysteine proteases of Trichomonas vaginalis degrade secretory leukocyte protease inhibitor.
Draper D; Donohoe W; Mortimer L; Heine RP
J Infect Dis; 1998 Sep; 178(3):815-9. PubMed ID: 9728551
[TBL] [Abstract][Full Text] [Related]
18. Human immunodeficiency virus type-1 (HIV-1) replication is unaffected by human secretory leukocyte protease inhibitor.
Turpin JA; Schaeffer CA; Bu M; Graham L; Buckheit RW; Clanton D; Rice WG
Antiviral Res; 1996 Mar; 29(2-3):269-77. PubMed ID: 8739605
[TBL] [Abstract][Full Text] [Related]
19. Endogenous mucosal antiviral factors of the oral cavity.
Shugars DC
J Infect Dis; 1999 May; 179 Suppl 3():S431-5. PubMed ID: 10099113
[TBL] [Abstract][Full Text] [Related]
20. Secretory leukocyte protease inhibitor and its potential interactions with elastase and cathepsin B in gingival crevicular fluid and saliva from patients with chronic periodontitis.
Cox SW; Rodriguez-Gonzalez EM; Booth V; Eley BM
J Periodontal Res; 2006 Oct; 41(5):477-85. PubMed ID: 16953825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
